COMP <GO>
SUPN vs MRK // PIOTROSKI F-SCORE QUALITY
Supernus Pharmaceuticals Inc. (NASDAQ) VS. Merck & Company Inc. Common Stock (new) (NYSE) • 15-METRIC TALLY: SUPN 3
— MRK 10
■ METRIC PARITY
LAST: $41.92 (+0.19%) • MKT CAP: $2.43B
piotroski-score
7/9
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
piotroski-score
7/9
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SUPN VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | SUPN | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 89.60% | 74.80% | +14.80 | SUPN | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -4.50% | 20.70% | -25.20 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 15.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 1.89% | 3.42% | -1.53 | MRK | /fcf-yield <GO> |
| Operating Margin | -8.70% | 34.30% | -43.00 | MRK | /operating-margins <GO> |
| Net Profit Margin | -5.40% | 28.10% | -33.50 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 8.60% | 1.30% | +7.30 | SUPN | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 4.84 | 5.19 | -0.35 | MRK | /balance-sheet <GO> |
| Piotroski F-Score Quality ACTIVE | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.50% | 6.60% | -0.10 | SUPN | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 51.0 | 56.9 | -5.87 | MRK | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.88 | 0.92 | -0.04 | MRK | /macro-sensitivity <GO> |
| Forward P/E Multiple | 22.0x | 18.4x | +3.60 | MRK | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.43B | $361.02B | -$358.59B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | SUPN REV | MRK REV | SUPN GROSS % | MRK GROSS % | SUPN FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $719.0M | $65.01B | 89.6% | 74.8% | $46.0M | $12.36B |
| FY 2024 | $661.8M | $64.17B | 88.2% | 76.3% | $171.2M | $18.10B |
| FY 2023 | $607.5M | $60.12B | 44.0% | 44.0% | $83.7M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SUPN // BETA 0.88
MRK // BETA 0.92